Susan00 personal page - To The Moon

Susan00

Susan00

No personal profile

2Follow

2Followers

0Topic

0Badge

2021-09-23

Ok

Sorry, the original content has been removed

2021-09-18

Ok

Pfizer Covid-19 shot's protection against hospitalisation wanes in study

2021-09-11

Ok

The S&P 500 Has Had a Good Run. Why Wall Street Thinks a Pullback Is Coming.

2021-09-12

Ok

BlackBerry Has a Chance at Turning Into a Growth Stock

2021-05-06

Comment

The Bill And Melinda Gates Divorce: $130B And More Is At Stake

2021-09-22

Ok

Sorry, the original content has been removed

2021-09-07

Ok

3 Value Stocks That'll Make You Richer in September (and Beyond)

2021-09-07

Ok

3 Value Stocks That'll Make You Richer in September (and Beyond)

2021-09-20

Ok

The One Indicator That Has Wall Street Biting Its Nails

2021-09-16

Ok

Procept BioRobotics spikes 40% on its first day of trading

2021-09-14

Ok

Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO

2021-05-06

Comment

Shares of China vaccine makers slump on U.S. waiver support

2021-05-06

Comment

Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3579914987797156,"uuid":"3579914987797156","gmtCreate":1616820963783,"gmtModify":1631016818175,"name":"Susan00","pinyin":"susan00","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":2,"tweetSize":29,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.87%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":863494591,"gmtCreate":1632410273513,"gmtModify":1676530776879,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863494591","repostId":"1162776746","repostType":4,"isVote":1,"tweetType":1,"viewCount":337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869833268,"gmtCreate":1632271211254,"gmtModify":1676530739250,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869833268","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860065579,"gmtCreate":1632108770691,"gmtModify":1676530702810,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860065579","repostId":"1196172424","repostType":4,"repost":{"id":"1196172424","pubTimestamp":1632105381,"share":"https://www.laohu8.com/m/news/1196172424?lang=&edition=full","pubTime":"2021-09-20 10:36","market":"us","language":"en","title":"The One Indicator That Has Wall Street Biting Its Nails","url":"https://stock-news.laohu8.com/highlight/detail?id=1196172424","media":"Barrons","summary":"The stock market dropped because there’s something scarier than taxes, tapers, and contagion.","content":"<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.</p>\n<p>The predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.</p>\n<p>But then the&nbsp;S&amp;P 500&nbsp;dropped 0.6%, to 4432.99, over the week, while the&nbsp;Dow Jones Industrial Average&nbsp;fell 0.1%, to 34,584.88, and the&nbsp;Nasdaq Composite&nbsp;slumped 0.5%, to 15,043.97. For the S&amp;P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.</p>\n<p>That the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&amp;P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.</p>\n<p>“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”</p>\n<p>This time has a different feel to it. The S&amp;P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”</p>\n<p>Still, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&amp;P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.</p>\n<p>The market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.</p>\n<p>But perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”</p>\n<p>We just have to get there first.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The One Indicator That Has Wall Street Biting Its Nails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe One Indicator That Has Wall Street Biting Its Nails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past ...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196172424","content_text":"Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.\nBut then the S&P 500 dropped 0.6%, to 4432.99, over the week, while the Dow Jones Industrial Average fell 0.1%, to 34,584.88, and the Nasdaq Composite slumped 0.5%, to 15,043.97. For the S&P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.\nThat the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.\n“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”\nThis time has a different feel to it. The S&P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”\nStill, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.\nThe market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.\nBut perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”\nWe just have to get there first.","news_type":1},"isVote":1,"tweetType":1,"viewCount":191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887095717,"gmtCreate":1631940454639,"gmtModify":1676530675125,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887095717","repostId":"2168574191","repostType":4,"repost":{"id":"2168574191","pubTimestamp":1631928823,"share":"https://www.laohu8.com/m/news/2168574191?lang=&edition=full","pubTime":"2021-09-18 09:33","market":"us","language":"en","title":"Pfizer Covid-19 shot's protection against hospitalisation wanes in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2168574191","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation af","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Covid-19 shot's protection against hospitalisation wanes in study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Covid-19 shot's protection against hospitalisation wanes in study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 09:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168574191","content_text":"WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from 21 US hospitals across 18 states.\nTwo doses of either vaccine provided more protection against hospitalisation than the one-dose Johnson & Johnson vaccine, the study found, though Pfizer's advantage over J&J narrowed over time, according to the study published on Friday (Sept 17) by the Centres for Disease Control and Prevention with collaborators across the country.\nAll three vaccines provided substantial protection after four months - Moderna's was 92 per cent effective against hospitalisation by then, with Pfizer's at 77 per cent and J&J at 68 per cent.\nThe data, published on Friday, may influence the debate over whether Americans should receive a third dose of vaccine to ward off the virus.\nAdvisers to the Food and Drug Administration are expected to vote on Friday on whether to recommend a booster shot, and they've mostly had to rely on data from Israel and the UK on whether the shots' effectiveness wanes over time.\nThe US is facing a surge of Covid-19 infections fuelled by the highly transmissible Delta variant, particularly among unvaccinated parts of the country, and breakthrough infections among vaccinated people have become more common.\nThe CDC study looked at 3,689 non-immunocompromised adults from March to August. The researchers noted that the vaccine effectiveness differences between Moderna and Pfizer's shots, which both use a mechanism called messenger RNA, could be due to differences in timings between doses.\nThe second dose of the Pfizer vaccine is typically delivered after three weeks, while Moderna patients wait four weeks.\nThey also noted several limitations to the study, including the fact that a relatively small number of patients had received the J&J vaccine compared with the mRNA vaccines.\nPrevious studies have found that Moderna's vaccine appears to generate more antibodies than Pfizer's, though it's not clear if antibodies are even the most important component in immunity over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885047801,"gmtCreate":1631748514103,"gmtModify":1676530622767,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885047801","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://www.laohu8.com/m/news/2167559884?lang=&edition=full","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886623643,"gmtCreate":1631587216582,"gmtModify":1676530583181,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886623643","repostId":"2167352505","repostType":4,"repost":{"id":"2167352505","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631580300,"share":"https://www.laohu8.com/m/news/2167352505?lang=&edition=full","pubTime":"2021-09-14 08:45","market":"us","language":"en","title":"Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2167352505","media":"Reuters","summary":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots ","content":"<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-14 08:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","TAK":"武田制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167352505","content_text":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.\nTakeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.\nBut vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.\nVaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.\n\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.\nTakeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.\nThe company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.\nJapan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.\nAbout 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.\nWeber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.\nWith some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.\n\"We don't rely on one product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888035192,"gmtCreate":1631412487716,"gmtModify":1676530542958,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888035192","repostId":"1127699574","repostType":4,"repost":{"id":"1127699574","pubTimestamp":1631328152,"share":"https://www.laohu8.com/m/news/1127699574?lang=&edition=full","pubTime":"2021-09-11 10:42","market":"us","language":"en","title":"BlackBerry Has a Chance at Turning Into a Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1127699574","media":"InvestorPlace","summary":"BB stock could be worth 30% more, assuming the company turns FCF positive next fiscal year","content":"<p><b>Blackberry</b>&nbsp;(NYSE:<b><u>BB</u></b>), the automotive embedded software company, produced positive free cash flow (FCF)&nbsp;of $74 million&nbsp;last fiscal year ending May 31. But its fiscal&nbsp;Q1 showed a loss of $35 million in FCF. This didn’t do anything to help BB stock. If fell from a near-term peak of $15.88 on June 3 (before the June 24 Q1 results) to $9.56 on Aug. 19. The stock could be near a trough now.</p>\n<p>I still believe that&nbsp;as I wrote on June 4, BB stock could be worth $20.91 per share, assuming its FCF turns positive this year. All eyes will therefore be on its upcoming Sept. 22 fiscal Q2 earnings release. Investors will want to see if revenue is growing and the company achieves positive FCF.</p>\n<p>For example, last quarter ending May 31 revenue fell by 15.5% year-over-year (YOY) from $206 million last year to $174 million this quarter. In fact, it was also down by 17.1% from the prior quarter as well.</p>\n<p>That is almost like a curse for a stock like Blackberry. Investors and analysts want to see positive growth on a steady YoY and quarter-over-quarter (QOQ) basis. This probably explains why the stock fell so much.</p>\n<p><b>Where This Leaves BlackBerry</b></p>\n<p>Last year BlackBerry produced $893 million in revenue, but for this fiscal year ending May 2022 analysts still see lower sales at $781.6 million. However, they also expect a recovery by May 2023 to $954.1 million. But is the market willing to wait until then? That is why the upcoming fiscal Q2 2022 earnings release will be so important. Investors want to see if the company is back on a growth track.</p>\n<p>If it is, then the likelihood that it can produce positive free cash flow for the year will increase, and this will help BB stock recover.</p>\n<p>For example, as I pointed out in my last article, BlackBerry reported FCF during Q4 of $49 million. This was a huge 23.33% of its $210 million in revenue during the quarter. Assuming it can pull off the same thing next year the company could make $222.3 million in FCF that year. That is based on 23.33% of sales of $954.1 million.</p>\n<p>However, to be more conservative let’s assume that it can only make half of that or an 11.5% FCF margin. That lowers its forecast FCF to $109.7 million. Moreover, its present value using a 10% discount rate and a year and a half in the future is 86.68% times this FCF number. That lowers it to $95.1 million.</p>\n<p><b>What BlackBerry Stock Could Be Worth</b></p>\n<p>If we use an FCF yield of between 1% we can calculate the company’s ongoing value. This is calculated by dividing the free cash flow estimates by its FCF yield ratio.</p>\n<p>For example, using $95.1 million in FCF forecast for Blackberry in 2023 brings its value to $9.51 billion. This is 55.7% over today’s market value for Blackberry of $6.109 billion.</p>\n<p>And if we use a 1.5% FCF yield, the target market value falls to $6.34 billion (i.e., $95.1/0.015=$6.34b). That is just 3.78% over today’s price.</p>\n<p>Therefore, BB stock has a target value between 3.78% and 55.7% over today’s price. The average is 29.74%, or basically 30% over today’s price of $10.73. That puts its value at $13.95 per share (estimate rounded to $14).</p>\n<p><b>What to do With BB Stock</b></p>\n<p>Analysts are not very positive about BB stock. For example, seven analysts surveyed by Refinitiv (reported by&nbsp;<i>Yahoo! Finance</i>) have an average target price of $8.36. That implies a potential drop of 22% from today’s price.</p>\n<p>Another survey by&nbsp;<i>TipRanks.com</i>&nbsp;says that four analysts have an&nbsp;average price of $9.50or 11.5% below today’s price. However, nine Wall Street analysts surveyed by&nbsp;<i>Seeking Alpha</i>&nbsp;have an&nbsp;average target of $8.19, or 23.7% below today.</p>\n<p>So the average of all three of these surveys is a price of $8.68, or 19% lower. I would not be too bothered by this though. Analysts have a tendency to raise their price targets after the stock has already risen.</p>\n<p>Enterprising investors who are willing to anticipate more positive results for the year ending May 2023 (and probably before that) could see the stock rise 30% to $13.95 per share.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlackBerry Has a Chance at Turning Into a Growth Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlackBerry Has a Chance at Turning Into a Growth Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-11 10:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Blackberry (NYSE:BB), the automotive embedded software company, produced positive free cash flow (FCF) of $74 million last fiscal year ending May 31. But its fiscal Q1 showed a loss of $35 million in ...</p>\n\n<a href=\"https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓"},"source_url":"https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127699574","content_text":"Blackberry (NYSE:BB), the automotive embedded software company, produced positive free cash flow (FCF) of $74 million last fiscal year ending May 31. But its fiscal Q1 showed a loss of $35 million in FCF. This didn’t do anything to help BB stock. If fell from a near-term peak of $15.88 on June 3 (before the June 24 Q1 results) to $9.56 on Aug. 19. The stock could be near a trough now.\nI still believe that as I wrote on June 4, BB stock could be worth $20.91 per share, assuming its FCF turns positive this year. All eyes will therefore be on its upcoming Sept. 22 fiscal Q2 earnings release. Investors will want to see if revenue is growing and the company achieves positive FCF.\nFor example, last quarter ending May 31 revenue fell by 15.5% year-over-year (YOY) from $206 million last year to $174 million this quarter. In fact, it was also down by 17.1% from the prior quarter as well.\nThat is almost like a curse for a stock like Blackberry. Investors and analysts want to see positive growth on a steady YoY and quarter-over-quarter (QOQ) basis. This probably explains why the stock fell so much.\nWhere This Leaves BlackBerry\nLast year BlackBerry produced $893 million in revenue, but for this fiscal year ending May 2022 analysts still see lower sales at $781.6 million. However, they also expect a recovery by May 2023 to $954.1 million. But is the market willing to wait until then? That is why the upcoming fiscal Q2 2022 earnings release will be so important. Investors want to see if the company is back on a growth track.\nIf it is, then the likelihood that it can produce positive free cash flow for the year will increase, and this will help BB stock recover.\nFor example, as I pointed out in my last article, BlackBerry reported FCF during Q4 of $49 million. This was a huge 23.33% of its $210 million in revenue during the quarter. Assuming it can pull off the same thing next year the company could make $222.3 million in FCF that year. That is based on 23.33% of sales of $954.1 million.\nHowever, to be more conservative let’s assume that it can only make half of that or an 11.5% FCF margin. That lowers its forecast FCF to $109.7 million. Moreover, its present value using a 10% discount rate and a year and a half in the future is 86.68% times this FCF number. That lowers it to $95.1 million.\nWhat BlackBerry Stock Could Be Worth\nIf we use an FCF yield of between 1% we can calculate the company’s ongoing value. This is calculated by dividing the free cash flow estimates by its FCF yield ratio.\nFor example, using $95.1 million in FCF forecast for Blackberry in 2023 brings its value to $9.51 billion. This is 55.7% over today’s market value for Blackberry of $6.109 billion.\nAnd if we use a 1.5% FCF yield, the target market value falls to $6.34 billion (i.e., $95.1/0.015=$6.34b). That is just 3.78% over today’s price.\nTherefore, BB stock has a target value between 3.78% and 55.7% over today’s price. The average is 29.74%, or basically 30% over today’s price of $10.73. That puts its value at $13.95 per share (estimate rounded to $14).\nWhat to do With BB Stock\nAnalysts are not very positive about BB stock. For example, seven analysts surveyed by Refinitiv (reported by Yahoo! Finance) have an average target price of $8.36. That implies a potential drop of 22% from today’s price.\nAnother survey by TipRanks.com says that four analysts have an average price of $9.50or 11.5% below today’s price. However, nine Wall Street analysts surveyed by Seeking Alpha have an average target of $8.19, or 23.7% below today.\nSo the average of all three of these surveys is a price of $8.68, or 19% lower. I would not be too bothered by this though. Analysts have a tendency to raise their price targets after the stock has already risen.\nEnterprising investors who are willing to anticipate more positive results for the year ending May 2023 (and probably before that) could see the stock rise 30% to $13.95 per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881860971,"gmtCreate":1631324095293,"gmtModify":1676530528328,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/881860971","repostId":"1105074635","repostType":4,"repost":{"id":"1105074635","pubTimestamp":1631321029,"share":"https://www.laohu8.com/m/news/1105074635?lang=&edition=full","pubTime":"2021-09-11 08:43","market":"us","language":"en","title":"The S&P 500 Has Had a Good Run. Why Wall Street Thinks a Pullback Is Coming.","url":"https://stock-news.laohu8.com/highlight/detail?id=1105074635","media":"Barrons","summary":"S&P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, ","content":"<p>S&amp;P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, says another—but they’ll lose money over the next decade. I can’t decide whether to panic or just sulk.</p>\n<p>The index decides the fate of more than $5 trillion in linked investor assets. My only exposure is in my retirement, joint, college, healthcare, and, come to think of it, all other investment accounts. I don’t think my Chipotle Rewards account is affected, but I haven’t read the small print.</p>\n<p>The concern, of course, is that S&amp;P 500 trackers have had it too good for too long. The index has returned 376% over the past decade, or close to 17% a year, compounded. Among active managers tasked with beating the index, four out of five failed during the 10 years through 2020.</p>\n<p>For Bogleheads, as devotees of the late Vanguard founder and indexing pioneer John Bogle call themselves, the explanation is simple: Stock-picking is futile. But if that’s so, the typical active manager should do no better or worse than indexes on underlying stock performance, and underperform only to the extent he or she charges extra fees. In fact, they have trailed over 10 years by an average of 2.5% a year. Stinking that badly is a skill of its own—one that theoretically shouldn’t exist.</p>\n<p>Another explanation is that the S&amp;P 500’s popularity has created its own tailwind. “Flows into index funds raise the prices of large stocks,” conclude researchers from Michigan State University, the London School of Economics, and the University of California, Irvine,in a working paper&nbsp;that has been circulating since late last year. By now, you’ve heard that five companies&nbsp;—&nbsp;Apple,Microsoft,Alphabet,Amazon.com,and&nbsp;Facebook—combined for one-quarter of the S&amp;P 500’s market value. But all are still growing nicely, so why worry now?</p>\n<p>This past Tuesday, Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management, predicted a 10% to 15% slide for the S&amp;P 500 before year’s end, but she says that doesn’t make her bearish. She points out that most 12-month stretches contain a big pullback for the index, but that we haven’t had one since March 2020. Tech giants, she has noticed, have lately traded hand-in-hand with Treasuries, suggesting that investors have come to view them as havens.</p>\n<p>“Owning the index today in a global context is a relatively defensive position, and we believe that it’s time to play offense,” she says.</p>\n<p>In Shalett’s view, interest rates will rise as global economies rebound, putting pressure on stock valuations. She predicts upside earnings surprises and stock outperformance for cyclical sectors like financials, industrials, energy, and materials, and for some pockets of consumer services and healthcare. “We’re very excited about buying a lot of different stocks,” she says. “We’re just not super-psyched about owning the index.”</p>\n<p>On Wednesday, Bank of America Securities issued a similarly mixed signal. It raised its year-end S&amp;P 500 target from 3800 all the way to 4250, which sounds optimistic. But it referred to the change as a mark to market—something typically done obligingly by accountants, not enthusiastically by forecasters. Also, the new target implies a decline of 5% or so from recent levels. Indexers have already made an easy 20% this year, so why sweat a holiday haircut? Because the bank is also predicting a 10-year average loss in the index of 0.8% a year.</p>\n<p>It’s devilishly difficult to predict short-term stock market returns. I tend to follow such forecasts more for the rationales than the targets. But long-term returns might be more closely linked than short-term ones to starting valuations, making forecasting more feasible. BofA says one measure has predicted about 80% of 10-year returns for the S&amp;P 500 since 1987: the ratio of the index’s price to what the bank calls its normalized earnings for the past 12 months. A typical reading is 19. The latest is 29. That has nudged the model’s predicted 10-year return below zero for the first time since 1999.</p>\n<p>BofA’s prescription is to buy dividend-growers and inflation beneficiaries like energy, financials, and materials. It also likes small-cap stocks, which it says are more closely tied than large-caps to U.S. economic growth, and have valuations that point to positive 10-year returns.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The S&P 500 Has Had a Good Run. Why Wall Street Thinks a Pullback Is Coming.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe S&P 500 Has Had a Good Run. Why Wall Street Thinks a Pullback Is Coming.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-11 08:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/sp-500-index-is-looking-vulnerable-51631313125?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>S&P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, says another—but they’ll lose money over the next decade. I can’t decide whether to panic or just ...</p>\n\n<a href=\"https://www.barrons.com/articles/sp-500-index-is-looking-vulnerable-51631313125?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/sp-500-index-is-looking-vulnerable-51631313125?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105074635","content_text":"S&P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, says another—but they’ll lose money over the next decade. I can’t decide whether to panic or just sulk.\nThe index decides the fate of more than $5 trillion in linked investor assets. My only exposure is in my retirement, joint, college, healthcare, and, come to think of it, all other investment accounts. I don’t think my Chipotle Rewards account is affected, but I haven’t read the small print.\nThe concern, of course, is that S&P 500 trackers have had it too good for too long. The index has returned 376% over the past decade, or close to 17% a year, compounded. Among active managers tasked with beating the index, four out of five failed during the 10 years through 2020.\nFor Bogleheads, as devotees of the late Vanguard founder and indexing pioneer John Bogle call themselves, the explanation is simple: Stock-picking is futile. But if that’s so, the typical active manager should do no better or worse than indexes on underlying stock performance, and underperform only to the extent he or she charges extra fees. In fact, they have trailed over 10 years by an average of 2.5% a year. Stinking that badly is a skill of its own—one that theoretically shouldn’t exist.\nAnother explanation is that the S&P 500’s popularity has created its own tailwind. “Flows into index funds raise the prices of large stocks,” conclude researchers from Michigan State University, the London School of Economics, and the University of California, Irvine,in a working paper that has been circulating since late last year. By now, you’ve heard that five companies — Apple,Microsoft,Alphabet,Amazon.com,and Facebook—combined for one-quarter of the S&P 500’s market value. But all are still growing nicely, so why worry now?\nThis past Tuesday, Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management, predicted a 10% to 15% slide for the S&P 500 before year’s end, but she says that doesn’t make her bearish. She points out that most 12-month stretches contain a big pullback for the index, but that we haven’t had one since March 2020. Tech giants, she has noticed, have lately traded hand-in-hand with Treasuries, suggesting that investors have come to view them as havens.\n“Owning the index today in a global context is a relatively defensive position, and we believe that it’s time to play offense,” she says.\nIn Shalett’s view, interest rates will rise as global economies rebound, putting pressure on stock valuations. She predicts upside earnings surprises and stock outperformance for cyclical sectors like financials, industrials, energy, and materials, and for some pockets of consumer services and healthcare. “We’re very excited about buying a lot of different stocks,” she says. “We’re just not super-psyched about owning the index.”\nOn Wednesday, Bank of America Securities issued a similarly mixed signal. It raised its year-end S&P 500 target from 3800 all the way to 4250, which sounds optimistic. But it referred to the change as a mark to market—something typically done obligingly by accountants, not enthusiastically by forecasters. Also, the new target implies a decline of 5% or so from recent levels. Indexers have already made an easy 20% this year, so why sweat a holiday haircut? Because the bank is also predicting a 10-year average loss in the index of 0.8% a year.\nIt’s devilishly difficult to predict short-term stock market returns. I tend to follow such forecasts more for the rationales than the targets. But long-term returns might be more closely linked than short-term ones to starting valuations, making forecasting more feasible. BofA says one measure has predicted about 80% of 10-year returns for the S&P 500 since 1987: the ratio of the index’s price to what the bank calls its normalized earnings for the past 12 months. A typical reading is 19. The latest is 29. That has nudged the model’s predicted 10-year return below zero for the first time since 1999.\nBofA’s prescription is to buy dividend-growers and inflation beneficiaries like energy, financials, and materials. It also likes small-cap stocks, which it says are more closely tied than large-caps to U.S. economic growth, and have valuations that point to positive 10-year returns.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302673,"gmtCreate":1631016775592,"gmtModify":1676530442898,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302673","repostId":"2165335391","repostType":4,"repost":{"id":"2165335391","pubTimestamp":1631015100,"share":"https://www.laohu8.com/m/news/2165335391?lang=&edition=full","pubTime":"2021-09-07 19:45","market":"us","language":"en","title":"3 Value Stocks That'll Make You Richer in September (and Beyond)","url":"https://stock-news.laohu8.com/highlight/detail?id=2165335391","media":"Motley Fool","summary":"These brand-name companies are simply too cheap for investors to pass up.","content":"<blockquote>\n <b>These brand-name companies are simply too cheap for investors to pass up.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Over the very long term, value stocks have outperformed growth stocks.</li>\n <li>Wall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.</li>\n</ul>\n<p>Since the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.</p>\n<p>In 2016, <b>Bank of America</b>/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.</p>\n<p>The following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.</p>\n<p><img src=\"https://static.tigerbbs.com/d19c9dd5972bb303415e3fb9e20fb2d4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Ford Motor Company</b></p>\n<p>The first value stock ready to do some burnouts in investors' portfolios is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Detroit's finest, <b>Ford Motor Company</b> (NYSE:F).</p>\n<p>Typically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.</p>\n<p>The multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.</p>\n<p>Keep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.</p>\n<p>Also, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, <i>vehicle</i>!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.</p>\n<p>Considering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.</p>\n<p><img src=\"https://static.tigerbbs.com/d3396d88a65200795f75b7c42368b2aa\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Western Digital</b></p>\n<p>If you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist <b>Western Digital</b> (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.</p>\n<p>The reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.</p>\n<p>Believe it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).</p>\n<p>The company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.</p>\n<p>But the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.</p>\n<p>Suffice it to say, Western Digital looks like a screaming bargain at its current valuation.</p>\n<p><img src=\"https://static.tigerbbs.com/0a442339ef77177eb97fecfa070c7ac0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Merck</b></p>\n<p>A third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant <b>Merck</b> (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.</p>\n<p>Whereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the <b>Dow Jones Industrial Average</b>'s worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of <b>Organon</b>&nbsp;in early June. However, neither of these issues are true long-term concerns.</p>\n<p>What investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.</p>\n<p>Just as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.</p>\n<p>The icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Value Stocks That'll Make You Richer in September (and Beyond)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Value Stocks That'll Make You Richer in September (and Beyond)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WDC":"西部数据","F":"福特汽车","MRK":"默沙东"},"source_url":"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165335391","content_text":"These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.\n\nSince the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.\nIn 2016, Bank of America/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.\nThe following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.\n\nImage source: Getty Images.\nFord Motor Company\nThe first value stock ready to do some burnouts in investors' portfolios is one of Detroit's finest, Ford Motor Company (NYSE:F).\nTypically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.\nThe multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.\nKeep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.\nAlso, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, vehicle!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.\nConsidering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.\n\nImage source: Getty Images.\nWestern Digital\nIf you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist Western Digital (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.\nThe reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.\nBelieve it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).\nThe company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.\nBut the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.\nSuffice it to say, Western Digital looks like a screaming bargain at its current valuation.\n\nImage source: Getty Images.\nMerck\nA third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant Merck (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.\nWhereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the Dow Jones Industrial Average's worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of Organon in early June. However, neither of these issues are true long-term concerns.\nWhat investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.\nJust as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.\nThe icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302139,"gmtCreate":1631016751621,"gmtModify":1676530442890,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302139","repostId":"2165335391","repostType":4,"repost":{"id":"2165335391","pubTimestamp":1631015100,"share":"https://www.laohu8.com/m/news/2165335391?lang=&edition=full","pubTime":"2021-09-07 19:45","market":"us","language":"en","title":"3 Value Stocks That'll Make You Richer in September (and Beyond)","url":"https://stock-news.laohu8.com/highlight/detail?id=2165335391","media":"Motley Fool","summary":"These brand-name companies are simply too cheap for investors to pass up.","content":"<blockquote>\n <b>These brand-name companies are simply too cheap for investors to pass up.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Over the very long term, value stocks have outperformed growth stocks.</li>\n <li>Wall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.</li>\n</ul>\n<p>Since the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.</p>\n<p>In 2016, <b>Bank of America</b>/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.</p>\n<p>The following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.</p>\n<p><img src=\"https://static.tigerbbs.com/d19c9dd5972bb303415e3fb9e20fb2d4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Ford Motor Company</b></p>\n<p>The first value stock ready to do some burnouts in investors' portfolios is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Detroit's finest, <b>Ford Motor Company</b> (NYSE:F).</p>\n<p>Typically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.</p>\n<p>The multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.</p>\n<p>Keep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.</p>\n<p>Also, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, <i>vehicle</i>!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.</p>\n<p>Considering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.</p>\n<p><img src=\"https://static.tigerbbs.com/d3396d88a65200795f75b7c42368b2aa\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Western Digital</b></p>\n<p>If you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist <b>Western Digital</b> (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.</p>\n<p>The reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.</p>\n<p>Believe it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).</p>\n<p>The company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.</p>\n<p>But the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.</p>\n<p>Suffice it to say, Western Digital looks like a screaming bargain at its current valuation.</p>\n<p><img src=\"https://static.tigerbbs.com/0a442339ef77177eb97fecfa070c7ac0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Merck</b></p>\n<p>A third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant <b>Merck</b> (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.</p>\n<p>Whereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the <b>Dow Jones Industrial Average</b>'s worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of <b>Organon</b>&nbsp;in early June. However, neither of these issues are true long-term concerns.</p>\n<p>What investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.</p>\n<p>Just as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.</p>\n<p>The icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Value Stocks That'll Make You Richer in September (and Beyond)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Value Stocks That'll Make You Richer in September (and Beyond)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WDC":"西部数据","F":"福特汽车","MRK":"默沙东"},"source_url":"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165335391","content_text":"These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.\n\nSince the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.\nIn 2016, Bank of America/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.\nThe following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.\n\nImage source: Getty Images.\nFord Motor Company\nThe first value stock ready to do some burnouts in investors' portfolios is one of Detroit's finest, Ford Motor Company (NYSE:F).\nTypically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.\nThe multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.\nKeep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.\nAlso, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, vehicle!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.\nConsidering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.\n\nImage source: Getty Images.\nWestern Digital\nIf you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist Western Digital (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.\nThe reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.\nBelieve it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).\nThe company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.\nBut the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.\nSuffice it to say, Western Digital looks like a screaming bargain at its current valuation.\n\nImage source: Getty Images.\nMerck\nA third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant Merck (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.\nWhereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the Dow Jones Industrial Average's worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of Organon in early June. However, neither of these issues are true long-term concerns.\nWhat investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.\nJust as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.\nThe icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.","news_type":1},"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890368,"gmtCreate":1620285601054,"gmtModify":1704341341405,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105890368","repostId":"1186255556","repostType":4,"repost":{"id":"1186255556","pubTimestamp":1620284285,"share":"https://www.laohu8.com/m/news/1186255556?lang=&edition=full","pubTime":"2021-05-06 14:58","market":"sh","language":"en","title":"Shares of China vaccine makers slump on U.S. waiver support","url":"https://stock-news.laohu8.com/highlight/detail?id=1186255556","media":"Reuters","summary":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. Presiden","content":"<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.</p><p>The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.</p><p>Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.</p><p>On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.</p><p>Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.</p><p>Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.</p><p>“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.</p><p>“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”</p><p>China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.</p><p>“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.</p><p>While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.</p><p>“Domestic sales are still their main source of revenue,” Wu said.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shares of China vaccine makers slump on U.S. waiver support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShares of China vaccine makers slump on U.S. waiver support\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines ...</p>\n\n<a href=\"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186255556","content_text":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.“Domestic sales are still their main source of revenue,” Wu said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890014,"gmtCreate":1620285585438,"gmtModify":1704341341078,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/105890014","repostId":"1148620968","repostType":4,"repost":{"id":"1148620968","pubTimestamp":1620271207,"share":"https://www.laohu8.com/m/news/1148620968?lang=&edition=full","pubTime":"2021-05-06 11:20","market":"us","language":"en","title":"The Bill And Melinda Gates Divorce: $130B And More Is At Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1148620968","media":"Benzinga","summary":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is ","content":"<p>When&nbsp;<b>Microsoft</b>MSFT 0.53%co-founder and ex-CEO Bill Gates announced the&nbsp;end of his marriage&nbsp;to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”</p><p>Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.</p><p>For those curious about how the other 1% live, here is a scorecard on the Gates’ wealth and what will be required when the time comes to divide their holdings after 27 years together.</p><p><b>Rules Of Disengagement:</b>One minor surprise arising from the news of the divorce was the absence of a prenuptial agreement, meaning&nbsp;there are no set boundaries to divide his from hers in this case.</p><p>Also complicating matters is state law: The couple live in Washington, which is a community property state. That means a judge could potentially divide their marital assets equally,&nbsp;&nbsp;which would mean Melinda could walk away with half of Bill’s $130-billion fortune.</p><p>One consideration that will not be part of the divorce proceedings is child support:&nbsp;Melinda stated it's unneeded, as their children are over the age of 18.</p><p><b>he Gates Property Empire:</b>Earlier this year, an investigation byThe Land Reportuncovered a rather surprising fact about Bill Gates: he is the single largest owner of U.S. farmland, with a portfolio of more than 268,000 acres spread over more than a dozen states. Because this property was acquired after the couple married, this will be considered part of the assets to be divided.</p><p>A separate report byWealth-Xfound Gates was the owner of a non-agricultural real estate portfolio worth more than $166 million. This portfolio includes the couple’s 66,000-square-foot lakeside home in Medina, Washington, which&nbsp;carries an estimated value of $65 million, along with a 30-acre estate in Wellington, Florida, a pair of luxury homes in California, a condo at Yellowstone Club in Big Sky, Montana and a private island in Belize.</p><p><b>Investment Assets:</b>Of course, no home is complete without tasteful furnishings, and Wealth-X pointed out that Gates has amassed an art collection valued at $130 million that includes the works of Andrew Wyeth and Winslow Homer.</p><p>Gates also has a notebook from Leonardo Da Vinci that he acquired for $30.8 million in a 1994 auction, as well as four rare first-edition copies of F. Scott Fitzgerald's \"The Great Gatsby.\"</p><p>Wealth-X has also catalogued Gates’ $650,000 sports car collection, which includes three flashy vehicles from<b>Porsche SE</b>POAHY 1.9%—&nbsp;a 1988 Porsche 959 Coupe, a Porsche 911 and a Porsche Carrera Cabriolet 964 —&nbsp;plus a Jaguar XJ6 and&nbsp;Ferrari 348.</p><p>But Gates’ most considerable asset would be his $29.9 billion in holdings in Cascade Investment, which covers nearly one-quarter of his total wealth.</p><p>Wealth-X determined Gates’ shareholdings through this company include an estimated $11.9 billion in<b>John Deere</b>DE 0.21%, $11 billion in<b>Canadian National Railway</b>CNI 1.09%and $1.6 billion in<b>Diageo plc</b>&nbsp;DEO 0.2%.</p><p>And while he is no longer running Microsoft, Gates still owns roughly $26.1 billion in shares.</p><p>As for the Bill &amp; Melinda Gates Foundation, the couple stated they would continue to work together on this philanthropic organization — and they transferred $20 billion of Microsoft stock into the foundation before announcing their divorce.</p><p>Bill will be represented in the divorce by the law firm Munger Tolles &amp; Olson, which was co-founded by Charlie Munger, vice chairman of<b>Berkshire Hathaway</b>(NYSE:BRK-A) (NYSE:BRK-B), while Melinda&nbsp;will have attorney representation from the New York City law firm Paul, Weiss, Rifkind, Wharton &amp; Garrison LLP.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bill And Melinda Gates Divorce: $130B And More Is At Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bill And Melinda Gates Divorce: $130B And More Is At Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates...</p>\n\n<a href=\"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148620968","content_text":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is a scorecard on the Gates’ wealth and what will be required when the time comes to divide their holdings after 27 years together.Rules Of Disengagement:One minor surprise arising from the news of the divorce was the absence of a prenuptial agreement, meaning there are no set boundaries to divide his from hers in this case.Also complicating matters is state law: The couple live in Washington, which is a community property state. That means a judge could potentially divide their marital assets equally,  which would mean Melinda could walk away with half of Bill’s $130-billion fortune.One consideration that will not be part of the divorce proceedings is child support: Melinda stated it's unneeded, as their children are over the age of 18.he Gates Property Empire:Earlier this year, an investigation byThe Land Reportuncovered a rather surprising fact about Bill Gates: he is the single largest owner of U.S. farmland, with a portfolio of more than 268,000 acres spread over more than a dozen states. Because this property was acquired after the couple married, this will be considered part of the assets to be divided.A separate report byWealth-Xfound Gates was the owner of a non-agricultural real estate portfolio worth more than $166 million. This portfolio includes the couple’s 66,000-square-foot lakeside home in Medina, Washington, which carries an estimated value of $65 million, along with a 30-acre estate in Wellington, Florida, a pair of luxury homes in California, a condo at Yellowstone Club in Big Sky, Montana and a private island in Belize.Investment Assets:Of course, no home is complete without tasteful furnishings, and Wealth-X pointed out that Gates has amassed an art collection valued at $130 million that includes the works of Andrew Wyeth and Winslow Homer.Gates also has a notebook from Leonardo Da Vinci that he acquired for $30.8 million in a 1994 auction, as well as four rare first-edition copies of F. Scott Fitzgerald's \"The Great Gatsby.\"Wealth-X has also catalogued Gates’ $650,000 sports car collection, which includes three flashy vehicles fromPorsche SEPOAHY 1.9%— a 1988 Porsche 959 Coupe, a Porsche 911 and a Porsche Carrera Cabriolet 964 — plus a Jaguar XJ6 and Ferrari 348.But Gates’ most considerable asset would be his $29.9 billion in holdings in Cascade Investment, which covers nearly one-quarter of his total wealth.Wealth-X determined Gates’ shareholdings through this company include an estimated $11.9 billion inJohn DeereDE 0.21%, $11 billion inCanadian National RailwayCNI 1.09%and $1.6 billion inDiageo plc DEO 0.2%.And while he is no longer running Microsoft, Gates still owns roughly $26.1 billion in shares.As for the Bill & Melinda Gates Foundation, the couple stated they would continue to work together on this philanthropic organization — and they transferred $20 billion of Microsoft stock into the foundation before announcing their divorce.Bill will be represented in the divorce by the law firm Munger Tolles & Olson, which was co-founded by Charlie Munger, vice chairman ofBerkshire Hathaway(NYSE:BRK-A) (NYSE:BRK-B), while Melinda will have attorney representation from the New York City law firm Paul, Weiss, Rifkind, Wharton & Garrison LLP.","news_type":1},"isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105807828,"gmtCreate":1620285542864,"gmtModify":1704341340106,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105807828","repostId":"1197402336","repostType":4,"repost":{"id":"1197402336","pubTimestamp":1620273156,"share":"https://www.laohu8.com/m/news/1197402336?lang=&edition=full","pubTime":"2021-05-06 11:52","market":"us","language":"en","title":"Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'","url":"https://stock-news.laohu8.com/highlight/detail?id=1197402336","media":"Benzinga","summary":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitco","content":"<p>Gains in&nbsp;<b>Ethereum Classic</b>(ETC) continue to outpace the ones made by the cryptocurrency’s peers&nbsp;<b>Bitcoin</b>(BTC),<b>Ethereum</b>(ETH), and<b>Dogecoin</b>(DOGE), which all enjoy larger market capitalizations.</p><p><b>What Happened:</b>ETC has soared 160.83% in a seven-day trailing period, while BTC and ETH have risen 3.54% and 26.80% in a similar period, according to CoinMarketCap data.</p><p>At press time on Wednesday night, ETC traded 16.85% higher at $90.06 in a 24-hour period. BTC was up 4.46% at $57,201.19 and ETH was higher by 3.71% at $3,484.</p><p>ETC is trading 10.43% below the all-time high of $100.03 it reached on Wednesday.</p><p>Ethereum Classiccame into existenceafter a hard fork of the Ethereum blockchain took place in 2016 due to prevailing disagreements at the time in the community.</p><p>Barry Silbert&nbsp;— CEO of Digital Currency Group, which owns Grayscale&nbsp;— is a well-known proponent of ETC.</p><p>On Wednesday, Ethereum Classic noted that the<b>Grayscale Ethereum Classic Trust</b>(OTC:ETCG) has over $1 billion in assets under management.<img src=\"https://static.tigerbbs.com/18a04b786e01b25f9feb9f9e93d0d366\" tg-width=\"555\" tg-height=\"892\" referrerpolicy=\"no-referrer\">ETCG closed 27.76% higher at $67.15 on Wednesday.</p><p><b>Why It Matters:</b>ETC has caught the attention of the social media investment crowd. The cryptocurrency’s ticker featured in the&nbsp;Stocktwits list of top 10 trending streams at press time.</p><p>The rise in ETC is despite the fact that it is not typically classified as an “Ethereum Killer,” which is thecase with several coinssuch as<b>Polkadot</b>(DOT),<b>Solana</b>(SOL), and<b>Cardano</b>(ADA).</p><p>Synergia Capital’s head of research, Denis Vinokourov, said that the rise in ETC “appears to be dominated by ‘cheaper’ Ethereum play and retail flow that has pushed DOGE to sky-high levels,” CoinDeskreported, dubbing the surge in ETC as a sign of froth in the cryptocurrency market.</p><p>ETC’s retail fueled rise is similar to the story of<b>Dogecoin</b>(DOGE), which has soared 13,604.64% since the year began. However, even DOGE’s weekly gains of 102.68% are weaker than those of ETC. DOGE traded 6.63% higher at $0.63 at press time.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197402336","content_text":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What Happened:ETC has soared 160.83% in a seven-day trailing period, while BTC and ETH have risen 3.54% and 26.80% in a similar period, according to CoinMarketCap data.At press time on Wednesday night, ETC traded 16.85% higher at $90.06 in a 24-hour period. BTC was up 4.46% at $57,201.19 and ETH was higher by 3.71% at $3,484.ETC is trading 10.43% below the all-time high of $100.03 it reached on Wednesday.Ethereum Classiccame into existenceafter a hard fork of the Ethereum blockchain took place in 2016 due to prevailing disagreements at the time in the community.Barry Silbert — CEO of Digital Currency Group, which owns Grayscale — is a well-known proponent of ETC.On Wednesday, Ethereum Classic noted that theGrayscale Ethereum Classic Trust(OTC:ETCG) has over $1 billion in assets under management.ETCG closed 27.76% higher at $67.15 on Wednesday.Why It Matters:ETC has caught the attention of the social media investment crowd. The cryptocurrency’s ticker featured in the Stocktwits list of top 10 trending streams at press time.The rise in ETC is despite the fact that it is not typically classified as an “Ethereum Killer,” which is thecase with several coinssuch asPolkadot(DOT),Solana(SOL), andCardano(ADA).Synergia Capital’s head of research, Denis Vinokourov, said that the rise in ETC “appears to be dominated by ‘cheaper’ Ethereum play and retail flow that has pushed DOGE to sky-high levels,” CoinDeskreported, dubbing the surge in ETC as a sign of froth in the cryptocurrency market.ETC’s retail fueled rise is similar to the story ofDogecoin(DOGE), which has soared 13,604.64% since the year began. However, even DOGE’s weekly gains of 102.68% are weaker than those of ETC. DOGE traded 6.63% higher at $0.63 at press time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":11,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":863494591,"gmtCreate":1632410273513,"gmtModify":1676530776879,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863494591","repostId":"1162776746","repostType":4,"isVote":1,"tweetType":1,"viewCount":337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887095717,"gmtCreate":1631940454639,"gmtModify":1676530675125,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887095717","repostId":"2168574191","repostType":4,"repost":{"id":"2168574191","pubTimestamp":1631928823,"share":"https://www.laohu8.com/m/news/2168574191?lang=&edition=full","pubTime":"2021-09-18 09:33","market":"us","language":"en","title":"Pfizer Covid-19 shot's protection against hospitalisation wanes in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2168574191","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation af","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Covid-19 shot's protection against hospitalisation wanes in study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Covid-19 shot's protection against hospitalisation wanes in study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 09:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168574191","content_text":"WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from 21 US hospitals across 18 states.\nTwo doses of either vaccine provided more protection against hospitalisation than the one-dose Johnson & Johnson vaccine, the study found, though Pfizer's advantage over J&J narrowed over time, according to the study published on Friday (Sept 17) by the Centres for Disease Control and Prevention with collaborators across the country.\nAll three vaccines provided substantial protection after four months - Moderna's was 92 per cent effective against hospitalisation by then, with Pfizer's at 77 per cent and J&J at 68 per cent.\nThe data, published on Friday, may influence the debate over whether Americans should receive a third dose of vaccine to ward off the virus.\nAdvisers to the Food and Drug Administration are expected to vote on Friday on whether to recommend a booster shot, and they've mostly had to rely on data from Israel and the UK on whether the shots' effectiveness wanes over time.\nThe US is facing a surge of Covid-19 infections fuelled by the highly transmissible Delta variant, particularly among unvaccinated parts of the country, and breakthrough infections among vaccinated people have become more common.\nThe CDC study looked at 3,689 non-immunocompromised adults from March to August. The researchers noted that the vaccine effectiveness differences between Moderna and Pfizer's shots, which both use a mechanism called messenger RNA, could be due to differences in timings between doses.\nThe second dose of the Pfizer vaccine is typically delivered after three weeks, while Moderna patients wait four weeks.\nThey also noted several limitations to the study, including the fact that a relatively small number of patients had received the J&J vaccine compared with the mRNA vaccines.\nPrevious studies have found that Moderna's vaccine appears to generate more antibodies than Pfizer's, though it's not clear if antibodies are even the most important component in immunity over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881860971,"gmtCreate":1631324095293,"gmtModify":1676530528328,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/881860971","repostId":"1105074635","repostType":4,"repost":{"id":"1105074635","pubTimestamp":1631321029,"share":"https://www.laohu8.com/m/news/1105074635?lang=&edition=full","pubTime":"2021-09-11 08:43","market":"us","language":"en","title":"The S&P 500 Has Had a Good Run. Why Wall Street Thinks a Pullback Is Coming.","url":"https://stock-news.laohu8.com/highlight/detail?id=1105074635","media":"Barrons","summary":"S&P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, ","content":"<p>S&amp;P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, says another—but they’ll lose money over the next decade. I can’t decide whether to panic or just sulk.</p>\n<p>The index decides the fate of more than $5 trillion in linked investor assets. My only exposure is in my retirement, joint, college, healthcare, and, come to think of it, all other investment accounts. I don’t think my Chipotle Rewards account is affected, but I haven’t read the small print.</p>\n<p>The concern, of course, is that S&amp;P 500 trackers have had it too good for too long. The index has returned 376% over the past decade, or close to 17% a year, compounded. Among active managers tasked with beating the index, four out of five failed during the 10 years through 2020.</p>\n<p>For Bogleheads, as devotees of the late Vanguard founder and indexing pioneer John Bogle call themselves, the explanation is simple: Stock-picking is futile. But if that’s so, the typical active manager should do no better or worse than indexes on underlying stock performance, and underperform only to the extent he or she charges extra fees. In fact, they have trailed over 10 years by an average of 2.5% a year. Stinking that badly is a skill of its own—one that theoretically shouldn’t exist.</p>\n<p>Another explanation is that the S&amp;P 500’s popularity has created its own tailwind. “Flows into index funds raise the prices of large stocks,” conclude researchers from Michigan State University, the London School of Economics, and the University of California, Irvine,in a working paper&nbsp;that has been circulating since late last year. By now, you’ve heard that five companies&nbsp;—&nbsp;Apple,Microsoft,Alphabet,Amazon.com,and&nbsp;Facebook—combined for one-quarter of the S&amp;P 500’s market value. But all are still growing nicely, so why worry now?</p>\n<p>This past Tuesday, Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management, predicted a 10% to 15% slide for the S&amp;P 500 before year’s end, but she says that doesn’t make her bearish. She points out that most 12-month stretches contain a big pullback for the index, but that we haven’t had one since March 2020. Tech giants, she has noticed, have lately traded hand-in-hand with Treasuries, suggesting that investors have come to view them as havens.</p>\n<p>“Owning the index today in a global context is a relatively defensive position, and we believe that it’s time to play offense,” she says.</p>\n<p>In Shalett’s view, interest rates will rise as global economies rebound, putting pressure on stock valuations. She predicts upside earnings surprises and stock outperformance for cyclical sectors like financials, industrials, energy, and materials, and for some pockets of consumer services and healthcare. “We’re very excited about buying a lot of different stocks,” she says. “We’re just not super-psyched about owning the index.”</p>\n<p>On Wednesday, Bank of America Securities issued a similarly mixed signal. It raised its year-end S&amp;P 500 target from 3800 all the way to 4250, which sounds optimistic. But it referred to the change as a mark to market—something typically done obligingly by accountants, not enthusiastically by forecasters. Also, the new target implies a decline of 5% or so from recent levels. Indexers have already made an easy 20% this year, so why sweat a holiday haircut? Because the bank is also predicting a 10-year average loss in the index of 0.8% a year.</p>\n<p>It’s devilishly difficult to predict short-term stock market returns. I tend to follow such forecasts more for the rationales than the targets. But long-term returns might be more closely linked than short-term ones to starting valuations, making forecasting more feasible. BofA says one measure has predicted about 80% of 10-year returns for the S&amp;P 500 since 1987: the ratio of the index’s price to what the bank calls its normalized earnings for the past 12 months. A typical reading is 19. The latest is 29. That has nudged the model’s predicted 10-year return below zero for the first time since 1999.</p>\n<p>BofA’s prescription is to buy dividend-growers and inflation beneficiaries like energy, financials, and materials. It also likes small-cap stocks, which it says are more closely tied than large-caps to U.S. economic growth, and have valuations that point to positive 10-year returns.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The S&P 500 Has Had a Good Run. Why Wall Street Thinks a Pullback Is Coming.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe S&P 500 Has Had a Good Run. Why Wall Street Thinks a Pullback Is Coming.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-11 08:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/sp-500-index-is-looking-vulnerable-51631313125?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>S&P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, says another—but they’ll lose money over the next decade. I can’t decide whether to panic or just ...</p>\n\n<a href=\"https://www.barrons.com/articles/sp-500-index-is-looking-vulnerable-51631313125?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/sp-500-index-is-looking-vulnerable-51631313125?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105074635","content_text":"S&P 500 index funds will tumble by Christmas, one Wall Street strategist predicts. Not necessarily, says another—but they’ll lose money over the next decade. I can’t decide whether to panic or just sulk.\nThe index decides the fate of more than $5 trillion in linked investor assets. My only exposure is in my retirement, joint, college, healthcare, and, come to think of it, all other investment accounts. I don’t think my Chipotle Rewards account is affected, but I haven’t read the small print.\nThe concern, of course, is that S&P 500 trackers have had it too good for too long. The index has returned 376% over the past decade, or close to 17% a year, compounded. Among active managers tasked with beating the index, four out of five failed during the 10 years through 2020.\nFor Bogleheads, as devotees of the late Vanguard founder and indexing pioneer John Bogle call themselves, the explanation is simple: Stock-picking is futile. But if that’s so, the typical active manager should do no better or worse than indexes on underlying stock performance, and underperform only to the extent he or she charges extra fees. In fact, they have trailed over 10 years by an average of 2.5% a year. Stinking that badly is a skill of its own—one that theoretically shouldn’t exist.\nAnother explanation is that the S&P 500’s popularity has created its own tailwind. “Flows into index funds raise the prices of large stocks,” conclude researchers from Michigan State University, the London School of Economics, and the University of California, Irvine,in a working paper that has been circulating since late last year. By now, you’ve heard that five companies — Apple,Microsoft,Alphabet,Amazon.com,and Facebook—combined for one-quarter of the S&P 500’s market value. But all are still growing nicely, so why worry now?\nThis past Tuesday, Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management, predicted a 10% to 15% slide for the S&P 500 before year’s end, but she says that doesn’t make her bearish. She points out that most 12-month stretches contain a big pullback for the index, but that we haven’t had one since March 2020. Tech giants, she has noticed, have lately traded hand-in-hand with Treasuries, suggesting that investors have come to view them as havens.\n“Owning the index today in a global context is a relatively defensive position, and we believe that it’s time to play offense,” she says.\nIn Shalett’s view, interest rates will rise as global economies rebound, putting pressure on stock valuations. She predicts upside earnings surprises and stock outperformance for cyclical sectors like financials, industrials, energy, and materials, and for some pockets of consumer services and healthcare. “We’re very excited about buying a lot of different stocks,” she says. “We’re just not super-psyched about owning the index.”\nOn Wednesday, Bank of America Securities issued a similarly mixed signal. It raised its year-end S&P 500 target from 3800 all the way to 4250, which sounds optimistic. But it referred to the change as a mark to market—something typically done obligingly by accountants, not enthusiastically by forecasters. Also, the new target implies a decline of 5% or so from recent levels. Indexers have already made an easy 20% this year, so why sweat a holiday haircut? Because the bank is also predicting a 10-year average loss in the index of 0.8% a year.\nIt’s devilishly difficult to predict short-term stock market returns. I tend to follow such forecasts more for the rationales than the targets. But long-term returns might be more closely linked than short-term ones to starting valuations, making forecasting more feasible. BofA says one measure has predicted about 80% of 10-year returns for the S&P 500 since 1987: the ratio of the index’s price to what the bank calls its normalized earnings for the past 12 months. A typical reading is 19. The latest is 29. That has nudged the model’s predicted 10-year return below zero for the first time since 1999.\nBofA’s prescription is to buy dividend-growers and inflation beneficiaries like energy, financials, and materials. It also likes small-cap stocks, which it says are more closely tied than large-caps to U.S. economic growth, and have valuations that point to positive 10-year returns.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888035192,"gmtCreate":1631412487716,"gmtModify":1676530542958,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888035192","repostId":"1127699574","repostType":4,"repost":{"id":"1127699574","pubTimestamp":1631328152,"share":"https://www.laohu8.com/m/news/1127699574?lang=&edition=full","pubTime":"2021-09-11 10:42","market":"us","language":"en","title":"BlackBerry Has a Chance at Turning Into a Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1127699574","media":"InvestorPlace","summary":"BB stock could be worth 30% more, assuming the company turns FCF positive next fiscal year","content":"<p><b>Blackberry</b>&nbsp;(NYSE:<b><u>BB</u></b>), the automotive embedded software company, produced positive free cash flow (FCF)&nbsp;of $74 million&nbsp;last fiscal year ending May 31. But its fiscal&nbsp;Q1 showed a loss of $35 million in FCF. This didn’t do anything to help BB stock. If fell from a near-term peak of $15.88 on June 3 (before the June 24 Q1 results) to $9.56 on Aug. 19. The stock could be near a trough now.</p>\n<p>I still believe that&nbsp;as I wrote on June 4, BB stock could be worth $20.91 per share, assuming its FCF turns positive this year. All eyes will therefore be on its upcoming Sept. 22 fiscal Q2 earnings release. Investors will want to see if revenue is growing and the company achieves positive FCF.</p>\n<p>For example, last quarter ending May 31 revenue fell by 15.5% year-over-year (YOY) from $206 million last year to $174 million this quarter. In fact, it was also down by 17.1% from the prior quarter as well.</p>\n<p>That is almost like a curse for a stock like Blackberry. Investors and analysts want to see positive growth on a steady YoY and quarter-over-quarter (QOQ) basis. This probably explains why the stock fell so much.</p>\n<p><b>Where This Leaves BlackBerry</b></p>\n<p>Last year BlackBerry produced $893 million in revenue, but for this fiscal year ending May 2022 analysts still see lower sales at $781.6 million. However, they also expect a recovery by May 2023 to $954.1 million. But is the market willing to wait until then? That is why the upcoming fiscal Q2 2022 earnings release will be so important. Investors want to see if the company is back on a growth track.</p>\n<p>If it is, then the likelihood that it can produce positive free cash flow for the year will increase, and this will help BB stock recover.</p>\n<p>For example, as I pointed out in my last article, BlackBerry reported FCF during Q4 of $49 million. This was a huge 23.33% of its $210 million in revenue during the quarter. Assuming it can pull off the same thing next year the company could make $222.3 million in FCF that year. That is based on 23.33% of sales of $954.1 million.</p>\n<p>However, to be more conservative let’s assume that it can only make half of that or an 11.5% FCF margin. That lowers its forecast FCF to $109.7 million. Moreover, its present value using a 10% discount rate and a year and a half in the future is 86.68% times this FCF number. That lowers it to $95.1 million.</p>\n<p><b>What BlackBerry Stock Could Be Worth</b></p>\n<p>If we use an FCF yield of between 1% we can calculate the company’s ongoing value. This is calculated by dividing the free cash flow estimates by its FCF yield ratio.</p>\n<p>For example, using $95.1 million in FCF forecast for Blackberry in 2023 brings its value to $9.51 billion. This is 55.7% over today’s market value for Blackberry of $6.109 billion.</p>\n<p>And if we use a 1.5% FCF yield, the target market value falls to $6.34 billion (i.e., $95.1/0.015=$6.34b). That is just 3.78% over today’s price.</p>\n<p>Therefore, BB stock has a target value between 3.78% and 55.7% over today’s price. The average is 29.74%, or basically 30% over today’s price of $10.73. That puts its value at $13.95 per share (estimate rounded to $14).</p>\n<p><b>What to do With BB Stock</b></p>\n<p>Analysts are not very positive about BB stock. For example, seven analysts surveyed by Refinitiv (reported by&nbsp;<i>Yahoo! Finance</i>) have an average target price of $8.36. That implies a potential drop of 22% from today’s price.</p>\n<p>Another survey by&nbsp;<i>TipRanks.com</i>&nbsp;says that four analysts have an&nbsp;average price of $9.50or 11.5% below today’s price. However, nine Wall Street analysts surveyed by&nbsp;<i>Seeking Alpha</i>&nbsp;have an&nbsp;average target of $8.19, or 23.7% below today.</p>\n<p>So the average of all three of these surveys is a price of $8.68, or 19% lower. I would not be too bothered by this though. Analysts have a tendency to raise their price targets after the stock has already risen.</p>\n<p>Enterprising investors who are willing to anticipate more positive results for the year ending May 2023 (and probably before that) could see the stock rise 30% to $13.95 per share.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlackBerry Has a Chance at Turning Into a Growth Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlackBerry Has a Chance at Turning Into a Growth Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-11 10:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Blackberry (NYSE:BB), the automotive embedded software company, produced positive free cash flow (FCF) of $74 million last fiscal year ending May 31. But its fiscal Q1 showed a loss of $35 million in ...</p>\n\n<a href=\"https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓"},"source_url":"https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127699574","content_text":"Blackberry (NYSE:BB), the automotive embedded software company, produced positive free cash flow (FCF) of $74 million last fiscal year ending May 31. But its fiscal Q1 showed a loss of $35 million in FCF. This didn’t do anything to help BB stock. If fell from a near-term peak of $15.88 on June 3 (before the June 24 Q1 results) to $9.56 on Aug. 19. The stock could be near a trough now.\nI still believe that as I wrote on June 4, BB stock could be worth $20.91 per share, assuming its FCF turns positive this year. All eyes will therefore be on its upcoming Sept. 22 fiscal Q2 earnings release. Investors will want to see if revenue is growing and the company achieves positive FCF.\nFor example, last quarter ending May 31 revenue fell by 15.5% year-over-year (YOY) from $206 million last year to $174 million this quarter. In fact, it was also down by 17.1% from the prior quarter as well.\nThat is almost like a curse for a stock like Blackberry. Investors and analysts want to see positive growth on a steady YoY and quarter-over-quarter (QOQ) basis. This probably explains why the stock fell so much.\nWhere This Leaves BlackBerry\nLast year BlackBerry produced $893 million in revenue, but for this fiscal year ending May 2022 analysts still see lower sales at $781.6 million. However, they also expect a recovery by May 2023 to $954.1 million. But is the market willing to wait until then? That is why the upcoming fiscal Q2 2022 earnings release will be so important. Investors want to see if the company is back on a growth track.\nIf it is, then the likelihood that it can produce positive free cash flow for the year will increase, and this will help BB stock recover.\nFor example, as I pointed out in my last article, BlackBerry reported FCF during Q4 of $49 million. This was a huge 23.33% of its $210 million in revenue during the quarter. Assuming it can pull off the same thing next year the company could make $222.3 million in FCF that year. That is based on 23.33% of sales of $954.1 million.\nHowever, to be more conservative let’s assume that it can only make half of that or an 11.5% FCF margin. That lowers its forecast FCF to $109.7 million. Moreover, its present value using a 10% discount rate and a year and a half in the future is 86.68% times this FCF number. That lowers it to $95.1 million.\nWhat BlackBerry Stock Could Be Worth\nIf we use an FCF yield of between 1% we can calculate the company’s ongoing value. This is calculated by dividing the free cash flow estimates by its FCF yield ratio.\nFor example, using $95.1 million in FCF forecast for Blackberry in 2023 brings its value to $9.51 billion. This is 55.7% over today’s market value for Blackberry of $6.109 billion.\nAnd if we use a 1.5% FCF yield, the target market value falls to $6.34 billion (i.e., $95.1/0.015=$6.34b). That is just 3.78% over today’s price.\nTherefore, BB stock has a target value between 3.78% and 55.7% over today’s price. The average is 29.74%, or basically 30% over today’s price of $10.73. That puts its value at $13.95 per share (estimate rounded to $14).\nWhat to do With BB Stock\nAnalysts are not very positive about BB stock. For example, seven analysts surveyed by Refinitiv (reported by Yahoo! Finance) have an average target price of $8.36. That implies a potential drop of 22% from today’s price.\nAnother survey by TipRanks.com says that four analysts have an average price of $9.50or 11.5% below today’s price. However, nine Wall Street analysts surveyed by Seeking Alpha have an average target of $8.19, or 23.7% below today.\nSo the average of all three of these surveys is a price of $8.68, or 19% lower. I would not be too bothered by this though. Analysts have a tendency to raise their price targets after the stock has already risen.\nEnterprising investors who are willing to anticipate more positive results for the year ending May 2023 (and probably before that) could see the stock rise 30% to $13.95 per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890014,"gmtCreate":1620285585438,"gmtModify":1704341341078,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/105890014","repostId":"1148620968","repostType":4,"repost":{"id":"1148620968","pubTimestamp":1620271207,"share":"https://www.laohu8.com/m/news/1148620968?lang=&edition=full","pubTime":"2021-05-06 11:20","market":"us","language":"en","title":"The Bill And Melinda Gates Divorce: $130B And More Is At Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1148620968","media":"Benzinga","summary":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is ","content":"<p>When&nbsp;<b>Microsoft</b>MSFT 0.53%co-founder and ex-CEO Bill Gates announced the&nbsp;end of his marriage&nbsp;to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”</p><p>Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.</p><p>For those curious about how the other 1% live, here is a scorecard on the Gates’ wealth and what will be required when the time comes to divide their holdings after 27 years together.</p><p><b>Rules Of Disengagement:</b>One minor surprise arising from the news of the divorce was the absence of a prenuptial agreement, meaning&nbsp;there are no set boundaries to divide his from hers in this case.</p><p>Also complicating matters is state law: The couple live in Washington, which is a community property state. That means a judge could potentially divide their marital assets equally,&nbsp;&nbsp;which would mean Melinda could walk away with half of Bill’s $130-billion fortune.</p><p>One consideration that will not be part of the divorce proceedings is child support:&nbsp;Melinda stated it's unneeded, as their children are over the age of 18.</p><p><b>he Gates Property Empire:</b>Earlier this year, an investigation byThe Land Reportuncovered a rather surprising fact about Bill Gates: he is the single largest owner of U.S. farmland, with a portfolio of more than 268,000 acres spread over more than a dozen states. Because this property was acquired after the couple married, this will be considered part of the assets to be divided.</p><p>A separate report byWealth-Xfound Gates was the owner of a non-agricultural real estate portfolio worth more than $166 million. This portfolio includes the couple’s 66,000-square-foot lakeside home in Medina, Washington, which&nbsp;carries an estimated value of $65 million, along with a 30-acre estate in Wellington, Florida, a pair of luxury homes in California, a condo at Yellowstone Club in Big Sky, Montana and a private island in Belize.</p><p><b>Investment Assets:</b>Of course, no home is complete without tasteful furnishings, and Wealth-X pointed out that Gates has amassed an art collection valued at $130 million that includes the works of Andrew Wyeth and Winslow Homer.</p><p>Gates also has a notebook from Leonardo Da Vinci that he acquired for $30.8 million in a 1994 auction, as well as four rare first-edition copies of F. Scott Fitzgerald's \"The Great Gatsby.\"</p><p>Wealth-X has also catalogued Gates’ $650,000 sports car collection, which includes three flashy vehicles from<b>Porsche SE</b>POAHY 1.9%—&nbsp;a 1988 Porsche 959 Coupe, a Porsche 911 and a Porsche Carrera Cabriolet 964 —&nbsp;plus a Jaguar XJ6 and&nbsp;Ferrari 348.</p><p>But Gates’ most considerable asset would be his $29.9 billion in holdings in Cascade Investment, which covers nearly one-quarter of his total wealth.</p><p>Wealth-X determined Gates’ shareholdings through this company include an estimated $11.9 billion in<b>John Deere</b>DE 0.21%, $11 billion in<b>Canadian National Railway</b>CNI 1.09%and $1.6 billion in<b>Diageo plc</b>&nbsp;DEO 0.2%.</p><p>And while he is no longer running Microsoft, Gates still owns roughly $26.1 billion in shares.</p><p>As for the Bill &amp; Melinda Gates Foundation, the couple stated they would continue to work together on this philanthropic organization — and they transferred $20 billion of Microsoft stock into the foundation before announcing their divorce.</p><p>Bill will be represented in the divorce by the law firm Munger Tolles &amp; Olson, which was co-founded by Charlie Munger, vice chairman of<b>Berkshire Hathaway</b>(NYSE:BRK-A) (NYSE:BRK-B), while Melinda&nbsp;will have attorney representation from the New York City law firm Paul, Weiss, Rifkind, Wharton &amp; Garrison LLP.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bill And Melinda Gates Divorce: $130B And More Is At Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bill And Melinda Gates Divorce: $130B And More Is At Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates...</p>\n\n<a href=\"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148620968","content_text":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is a scorecard on the Gates’ wealth and what will be required when the time comes to divide their holdings after 27 years together.Rules Of Disengagement:One minor surprise arising from the news of the divorce was the absence of a prenuptial agreement, meaning there are no set boundaries to divide his from hers in this case.Also complicating matters is state law: The couple live in Washington, which is a community property state. That means a judge could potentially divide their marital assets equally,  which would mean Melinda could walk away with half of Bill’s $130-billion fortune.One consideration that will not be part of the divorce proceedings is child support: Melinda stated it's unneeded, as their children are over the age of 18.he Gates Property Empire:Earlier this year, an investigation byThe Land Reportuncovered a rather surprising fact about Bill Gates: he is the single largest owner of U.S. farmland, with a portfolio of more than 268,000 acres spread over more than a dozen states. Because this property was acquired after the couple married, this will be considered part of the assets to be divided.A separate report byWealth-Xfound Gates was the owner of a non-agricultural real estate portfolio worth more than $166 million. This portfolio includes the couple’s 66,000-square-foot lakeside home in Medina, Washington, which carries an estimated value of $65 million, along with a 30-acre estate in Wellington, Florida, a pair of luxury homes in California, a condo at Yellowstone Club in Big Sky, Montana and a private island in Belize.Investment Assets:Of course, no home is complete without tasteful furnishings, and Wealth-X pointed out that Gates has amassed an art collection valued at $130 million that includes the works of Andrew Wyeth and Winslow Homer.Gates also has a notebook from Leonardo Da Vinci that he acquired for $30.8 million in a 1994 auction, as well as four rare first-edition copies of F. Scott Fitzgerald's \"The Great Gatsby.\"Wealth-X has also catalogued Gates’ $650,000 sports car collection, which includes three flashy vehicles fromPorsche SEPOAHY 1.9%— a 1988 Porsche 959 Coupe, a Porsche 911 and a Porsche Carrera Cabriolet 964 — plus a Jaguar XJ6 and Ferrari 348.But Gates’ most considerable asset would be his $29.9 billion in holdings in Cascade Investment, which covers nearly one-quarter of his total wealth.Wealth-X determined Gates’ shareholdings through this company include an estimated $11.9 billion inJohn DeereDE 0.21%, $11 billion inCanadian National RailwayCNI 1.09%and $1.6 billion inDiageo plc DEO 0.2%.And while he is no longer running Microsoft, Gates still owns roughly $26.1 billion in shares.As for the Bill & Melinda Gates Foundation, the couple stated they would continue to work together on this philanthropic organization — and they transferred $20 billion of Microsoft stock into the foundation before announcing their divorce.Bill will be represented in the divorce by the law firm Munger Tolles & Olson, which was co-founded by Charlie Munger, vice chairman ofBerkshire Hathaway(NYSE:BRK-A) (NYSE:BRK-B), while Melinda will have attorney representation from the New York City law firm Paul, Weiss, Rifkind, Wharton & Garrison LLP.","news_type":1},"isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869833268,"gmtCreate":1632271211254,"gmtModify":1676530739250,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869833268","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302139,"gmtCreate":1631016751621,"gmtModify":1676530442890,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302139","repostId":"2165335391","repostType":4,"repost":{"id":"2165335391","pubTimestamp":1631015100,"share":"https://www.laohu8.com/m/news/2165335391?lang=&edition=full","pubTime":"2021-09-07 19:45","market":"us","language":"en","title":"3 Value Stocks That'll Make You Richer in September (and Beyond)","url":"https://stock-news.laohu8.com/highlight/detail?id=2165335391","media":"Motley Fool","summary":"These brand-name companies are simply too cheap for investors to pass up.","content":"<blockquote>\n <b>These brand-name companies are simply too cheap for investors to pass up.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Over the very long term, value stocks have outperformed growth stocks.</li>\n <li>Wall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.</li>\n</ul>\n<p>Since the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.</p>\n<p>In 2016, <b>Bank of America</b>/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.</p>\n<p>The following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.</p>\n<p><img src=\"https://static.tigerbbs.com/d19c9dd5972bb303415e3fb9e20fb2d4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Ford Motor Company</b></p>\n<p>The first value stock ready to do some burnouts in investors' portfolios is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Detroit's finest, <b>Ford Motor Company</b> (NYSE:F).</p>\n<p>Typically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.</p>\n<p>The multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.</p>\n<p>Keep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.</p>\n<p>Also, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, <i>vehicle</i>!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.</p>\n<p>Considering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.</p>\n<p><img src=\"https://static.tigerbbs.com/d3396d88a65200795f75b7c42368b2aa\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Western Digital</b></p>\n<p>If you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist <b>Western Digital</b> (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.</p>\n<p>The reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.</p>\n<p>Believe it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).</p>\n<p>The company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.</p>\n<p>But the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.</p>\n<p>Suffice it to say, Western Digital looks like a screaming bargain at its current valuation.</p>\n<p><img src=\"https://static.tigerbbs.com/0a442339ef77177eb97fecfa070c7ac0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Merck</b></p>\n<p>A third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant <b>Merck</b> (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.</p>\n<p>Whereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the <b>Dow Jones Industrial Average</b>'s worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of <b>Organon</b>&nbsp;in early June. However, neither of these issues are true long-term concerns.</p>\n<p>What investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.</p>\n<p>Just as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.</p>\n<p>The icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Value Stocks That'll Make You Richer in September (and Beyond)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Value Stocks That'll Make You Richer in September (and Beyond)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WDC":"西部数据","F":"福特汽车","MRK":"默沙东"},"source_url":"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165335391","content_text":"These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.\n\nSince the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.\nIn 2016, Bank of America/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.\nThe following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.\n\nImage source: Getty Images.\nFord Motor Company\nThe first value stock ready to do some burnouts in investors' portfolios is one of Detroit's finest, Ford Motor Company (NYSE:F).\nTypically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.\nThe multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.\nKeep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.\nAlso, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, vehicle!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.\nConsidering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.\n\nImage source: Getty Images.\nWestern Digital\nIf you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist Western Digital (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.\nThe reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.\nBelieve it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).\nThe company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.\nBut the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.\nSuffice it to say, Western Digital looks like a screaming bargain at its current valuation.\n\nImage source: Getty Images.\nMerck\nA third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant Merck (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.\nWhereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the Dow Jones Industrial Average's worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of Organon in early June. However, neither of these issues are true long-term concerns.\nWhat investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.\nJust as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.\nThe icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.","news_type":1},"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302673,"gmtCreate":1631016775592,"gmtModify":1676530442898,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302673","repostId":"2165335391","repostType":4,"repost":{"id":"2165335391","pubTimestamp":1631015100,"share":"https://www.laohu8.com/m/news/2165335391?lang=&edition=full","pubTime":"2021-09-07 19:45","market":"us","language":"en","title":"3 Value Stocks That'll Make You Richer in September (and Beyond)","url":"https://stock-news.laohu8.com/highlight/detail?id=2165335391","media":"Motley Fool","summary":"These brand-name companies are simply too cheap for investors to pass up.","content":"<blockquote>\n <b>These brand-name companies are simply too cheap for investors to pass up.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Over the very long term, value stocks have outperformed growth stocks.</li>\n <li>Wall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.</li>\n</ul>\n<p>Since the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.</p>\n<p>In 2016, <b>Bank of America</b>/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.</p>\n<p>The following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.</p>\n<p><img src=\"https://static.tigerbbs.com/d19c9dd5972bb303415e3fb9e20fb2d4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Ford Motor Company</b></p>\n<p>The first value stock ready to do some burnouts in investors' portfolios is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Detroit's finest, <b>Ford Motor Company</b> (NYSE:F).</p>\n<p>Typically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.</p>\n<p>The multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.</p>\n<p>Keep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.</p>\n<p>Also, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, <i>vehicle</i>!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.</p>\n<p>Considering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.</p>\n<p><img src=\"https://static.tigerbbs.com/d3396d88a65200795f75b7c42368b2aa\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Western Digital</b></p>\n<p>If you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist <b>Western Digital</b> (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.</p>\n<p>The reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.</p>\n<p>Believe it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).</p>\n<p>The company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.</p>\n<p>But the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.</p>\n<p>Suffice it to say, Western Digital looks like a screaming bargain at its current valuation.</p>\n<p><img src=\"https://static.tigerbbs.com/0a442339ef77177eb97fecfa070c7ac0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Merck</b></p>\n<p>A third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant <b>Merck</b> (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.</p>\n<p>Whereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the <b>Dow Jones Industrial Average</b>'s worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of <b>Organon</b>&nbsp;in early June. However, neither of these issues are true long-term concerns.</p>\n<p>What investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.</p>\n<p>Just as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.</p>\n<p>The icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Value Stocks That'll Make You Richer in September (and Beyond)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Value Stocks That'll Make You Richer in September (and Beyond)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WDC":"西部数据","F":"福特汽车","MRK":"默沙东"},"source_url":"https://www.fool.com/investing/2021/09/07/3-value-stocks-thatll-make-you-richer-in-september/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165335391","content_text":"These brand-name companies are simply too cheap for investors to pass up.\n\nKey Points\n\nOver the very long term, value stocks have outperformed growth stocks.\nWall Street looks to be grossly undervaluing these time-tested companies despite their hearty growth prospects.\n\nSince the end of the Great Recession, all eyes have been on growth stocks. Historically low lending rates and abundant access to cheap capital have allowed fast-paced businesses to thrive. But pull the lens back a bit further and you'll see that value stocks are the true long-term outperformer.\nIn 2016, Bank of America/Merrill Lynch released a report that compared the performance of value stocks to growth stocks over a 90-year period (1926-2015). The result was a clear-cut outperformance for value: A 17% annual return for value stocks versus a 12.6% annual return for growth stocks. Even though value stocks may be playing second fiddle to growth stocks at the moment, they're a solid investment choice for people with a long-term mindset.\nThe following trio of brand-name value stocks all stand out as having the tools necessary to make investors richer in September, and most importantly, well beyond.\n\nImage source: Getty Images.\nFord Motor Company\nThe first value stock ready to do some burnouts in investors' portfolios is one of Detroit's finest, Ford Motor Company (NYSE:F).\nTypically, auto stocks like Ford are valued at single-digit price-to-earnings (P/E) multiples, which are well below those of the broader market. These low P/E ratios are a reflection of the cyclical nature of the auto industry, as well as the high debt levels automakers like Ford usually carry on their balance sheets. But after more than a decade of rather ho-hum performance, the long-awaited catalyst that could send Ford's shares notably higher has arrived.\nThe multi-decade opportunity awaiting Ford and its peers is the electrification of consumer and enterprise vehicles. Replacing combustion-engine vehicles won't happen overnight, but the demand to go green should lead to a sustainable uptick in sales and profit potential. With the full understanding of the opportunity that lies at its doorstep, Ford is pledging to spend at least $30 billion through 2025 on electric vehicles (EVs) and the development of batteries for its EVs. By 2025, it aims to have launched 30 new EVs worldwide.\nKeep in mind that while Ford is a well-known player in the U.S. market, it has its eyes set on being a major auto company in China, the world's largest auto market. Ford's established brand and infrastructure should give it a leg up on the mostly nascent EV competition in China.\nAlso, no discussion of Ford would be complete without noting how overwhelmingly strong sales of its F-Series pickups have been for decades. The F-Series has been the best-selling vehicle (not truck, vehicle!) in the U.S. for the past 39 years. Since trucks offer juicier margins than sedans, the F-Series continues to play a key role in advancing Ford's bottom line.\nConsidering how many catalysts are in Ford's sails, a forward P/E ratio of less than 7 doesn't do this company justice.\n\nImage source: Getty Images.\nWestern Digital\nIf you think Ford is cheap, based on its forward earnings potential, take a closer look at storage solutions specialist Western Digital (NASDAQ:WDC), which can be purchased for less than six times Wall Street's estimated fiscal 2022 earnings per share.\nThe reason Western Digital is so cheap has to do with storage being a highly cyclical and generally commoditized industry. Seemingly every couple of years, we see data storage companies contending with supply issues or pricing pressures. The thing to note, though, is that quite a few of these external pressures turn out to be one-time events, such as natural disasters, and are not an indication of poor supply and demand oversight.\nBelieve it or not, the pandemic has been a positive for Western Digital on multiple fronts. The company's storage business has seen a healthy boost from an increase in notebook and desktop sales, as well as growing industrial demand (this includes the storage needs for new automobiles).\nThe company is benefiting from the gaming console replacement cycle as well, which began late last year. New consoles are far more sophisticated than their predecessors, and as you can imagine, they require considerably more storage capacity. Western Digital is seeing a nice bump in sales from gaming.\nBut the most exciting opportunity for Western Digital looks to be its role in providing storage solutions for data centers. As businesses pushed their data into the cloud during the pandemic, it became readily apparent that storage needs would grow. While this is a positive for the company's well-known hard-disk drives, it's Western Digital's NAND flash solutions that could one day become the staple storage solution in data centers.\nSuffice it to say, Western Digital looks like a screaming bargain at its current valuation.\n\nImage source: Getty Images.\nMerck\nA third value stock with the potential to make you richer in September, and well beyond, is pharmaceutical giant Merck (NYSE:MRK). Shares of the company can currently be scooped up for a multiple of 12 times Wall Street's forecasted earnings for 2022.\nWhereas most healthcare stocks have fared exceptionally well over the trailing year, Merck's shares are actually down, which makes it one of the Dow Jones Industrial Average's worst performers. It would appear that Wall Street wasn't thrilled with Merck's coronavirus vaccine failing to impress in clinical studies (the program was subsequently abandoned), or that its earnings forecast was reduced following the spinoff of Organon in early June. However, neither of these issues are true long-term concerns.\nWhat investors should be paying attention to is Merck's fast-growing cancer immunotherapy, Keytruda. Sales of Merck's top-selling drug nearly hit $4.2 billion in the second quarter, putting it on pace for an annual sale run-rate of over $16 billion. Considering that Keytruda is being examined in dozens of clinical trials as a monotherapy and combination treatment, it has a really good chance to expand its label and become one of the best-selling drugs in the world.\nJust as intriguing is the exceptional growth Merck has been witnessing in its animal health division. Although livestock treatment sales are up by 18% this year, it's the 35% year-to-date uptick in companion animal revenue that's turning heads. Pet expenditures are virtually recession-proof, which makes this operating segment a good bet to drive sales and profits higher for a long time to come.\nThe icing on the cake is that investors can pocket a market-topping 3.4% annual yield while they wait for the investment community to come to its senses on Merck.","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860065579,"gmtCreate":1632108770691,"gmtModify":1676530702810,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860065579","repostId":"1196172424","repostType":4,"repost":{"id":"1196172424","pubTimestamp":1632105381,"share":"https://www.laohu8.com/m/news/1196172424?lang=&edition=full","pubTime":"2021-09-20 10:36","market":"us","language":"en","title":"The One Indicator That Has Wall Street Biting Its Nails","url":"https://stock-news.laohu8.com/highlight/detail?id=1196172424","media":"Barrons","summary":"The stock market dropped because there’s something scarier than taxes, tapers, and contagion.","content":"<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.</p>\n<p>The predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.</p>\n<p>But then the&nbsp;S&amp;P 500&nbsp;dropped 0.6%, to 4432.99, over the week, while the&nbsp;Dow Jones Industrial Average&nbsp;fell 0.1%, to 34,584.88, and the&nbsp;Nasdaq Composite&nbsp;slumped 0.5%, to 15,043.97. For the S&amp;P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.</p>\n<p>That the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&amp;P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.</p>\n<p>“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”</p>\n<p>This time has a different feel to it. The S&amp;P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”</p>\n<p>Still, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&amp;P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.</p>\n<p>The market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.</p>\n<p>But perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”</p>\n<p>We just have to get there first.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The One Indicator That Has Wall Street Biting Its Nails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe One Indicator That Has Wall Street Biting Its Nails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past ...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196172424","content_text":"Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.\nBut then the S&P 500 dropped 0.6%, to 4432.99, over the week, while the Dow Jones Industrial Average fell 0.1%, to 34,584.88, and the Nasdaq Composite slumped 0.5%, to 15,043.97. For the S&P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.\nThat the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.\n“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”\nThis time has a different feel to it. The S&P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”\nStill, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.\nThe market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.\nBut perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”\nWe just have to get there first.","news_type":1},"isVote":1,"tweetType":1,"viewCount":191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885047801,"gmtCreate":1631748514103,"gmtModify":1676530622767,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885047801","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://www.laohu8.com/m/news/2167559884?lang=&edition=full","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886623643,"gmtCreate":1631587216582,"gmtModify":1676530583181,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886623643","repostId":"2167352505","repostType":4,"repost":{"id":"2167352505","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631580300,"share":"https://www.laohu8.com/m/news/2167352505?lang=&edition=full","pubTime":"2021-09-14 08:45","market":"us","language":"en","title":"Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2167352505","media":"Reuters","summary":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots ","content":"<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-14 08:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","TAK":"武田制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167352505","content_text":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.\nTakeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.\nBut vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.\nVaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.\n\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.\nTakeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.\nThe company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.\nJapan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.\nAbout 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.\nWeber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.\nWith some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.\n\"We don't rely on one product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890368,"gmtCreate":1620285601054,"gmtModify":1704341341405,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105890368","repostId":"1186255556","repostType":4,"repost":{"id":"1186255556","pubTimestamp":1620284285,"share":"https://www.laohu8.com/m/news/1186255556?lang=&edition=full","pubTime":"2021-05-06 14:58","market":"sh","language":"en","title":"Shares of China vaccine makers slump on U.S. waiver support","url":"https://stock-news.laohu8.com/highlight/detail?id=1186255556","media":"Reuters","summary":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. Presiden","content":"<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.</p><p>The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.</p><p>Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.</p><p>On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.</p><p>Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.</p><p>Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.</p><p>“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.</p><p>“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”</p><p>China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.</p><p>“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.</p><p>While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.</p><p>“Domestic sales are still their main source of revenue,” Wu said.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shares of China vaccine makers slump on U.S. waiver support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShares of China vaccine makers slump on U.S. waiver support\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines ...</p>\n\n<a href=\"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186255556","content_text":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.“Domestic sales are still their main source of revenue,” Wu said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105807828,"gmtCreate":1620285542864,"gmtModify":1704341340106,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105807828","repostId":"1197402336","repostType":4,"repost":{"id":"1197402336","pubTimestamp":1620273156,"share":"https://www.laohu8.com/m/news/1197402336?lang=&edition=full","pubTime":"2021-05-06 11:52","market":"us","language":"en","title":"Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'","url":"https://stock-news.laohu8.com/highlight/detail?id=1197402336","media":"Benzinga","summary":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitco","content":"<p>Gains in&nbsp;<b>Ethereum Classic</b>(ETC) continue to outpace the ones made by the cryptocurrency’s peers&nbsp;<b>Bitcoin</b>(BTC),<b>Ethereum</b>(ETH), and<b>Dogecoin</b>(DOGE), which all enjoy larger market capitalizations.</p><p><b>What Happened:</b>ETC has soared 160.83% in a seven-day trailing period, while BTC and ETH have risen 3.54% and 26.80% in a similar period, according to CoinMarketCap data.</p><p>At press time on Wednesday night, ETC traded 16.85% higher at $90.06 in a 24-hour period. BTC was up 4.46% at $57,201.19 and ETH was higher by 3.71% at $3,484.</p><p>ETC is trading 10.43% below the all-time high of $100.03 it reached on Wednesday.</p><p>Ethereum Classiccame into existenceafter a hard fork of the Ethereum blockchain took place in 2016 due to prevailing disagreements at the time in the community.</p><p>Barry Silbert&nbsp;— CEO of Digital Currency Group, which owns Grayscale&nbsp;— is a well-known proponent of ETC.</p><p>On Wednesday, Ethereum Classic noted that the<b>Grayscale Ethereum Classic Trust</b>(OTC:ETCG) has over $1 billion in assets under management.<img src=\"https://static.tigerbbs.com/18a04b786e01b25f9feb9f9e93d0d366\" tg-width=\"555\" tg-height=\"892\" referrerpolicy=\"no-referrer\">ETCG closed 27.76% higher at $67.15 on Wednesday.</p><p><b>Why It Matters:</b>ETC has caught the attention of the social media investment crowd. The cryptocurrency’s ticker featured in the&nbsp;Stocktwits list of top 10 trending streams at press time.</p><p>The rise in ETC is despite the fact that it is not typically classified as an “Ethereum Killer,” which is thecase with several coinssuch as<b>Polkadot</b>(DOT),<b>Solana</b>(SOL), and<b>Cardano</b>(ADA).</p><p>Synergia Capital’s head of research, Denis Vinokourov, said that the rise in ETC “appears to be dominated by ‘cheaper’ Ethereum play and retail flow that has pushed DOGE to sky-high levels,” CoinDeskreported, dubbing the surge in ETC as a sign of froth in the cryptocurrency market.</p><p>ETC’s retail fueled rise is similar to the story of<b>Dogecoin</b>(DOGE), which has soared 13,604.64% since the year began. However, even DOGE’s weekly gains of 102.68% are weaker than those of ETC. DOGE traded 6.63% higher at $0.63 at press time.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197402336","content_text":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What Happened:ETC has soared 160.83% in a seven-day trailing period, while BTC and ETH have risen 3.54% and 26.80% in a similar period, according to CoinMarketCap data.At press time on Wednesday night, ETC traded 16.85% higher at $90.06 in a 24-hour period. BTC was up 4.46% at $57,201.19 and ETH was higher by 3.71% at $3,484.ETC is trading 10.43% below the all-time high of $100.03 it reached on Wednesday.Ethereum Classiccame into existenceafter a hard fork of the Ethereum blockchain took place in 2016 due to prevailing disagreements at the time in the community.Barry Silbert — CEO of Digital Currency Group, which owns Grayscale — is a well-known proponent of ETC.On Wednesday, Ethereum Classic noted that theGrayscale Ethereum Classic Trust(OTC:ETCG) has over $1 billion in assets under management.ETCG closed 27.76% higher at $67.15 on Wednesday.Why It Matters:ETC has caught the attention of the social media investment crowd. The cryptocurrency’s ticker featured in the Stocktwits list of top 10 trending streams at press time.The rise in ETC is despite the fact that it is not typically classified as an “Ethereum Killer,” which is thecase with several coinssuch asPolkadot(DOT),Solana(SOL), andCardano(ADA).Synergia Capital’s head of research, Denis Vinokourov, said that the rise in ETC “appears to be dominated by ‘cheaper’ Ethereum play and retail flow that has pushed DOGE to sky-high levels,” CoinDeskreported, dubbing the surge in ETC as a sign of froth in the cryptocurrency market.ETC’s retail fueled rise is similar to the story ofDogecoin(DOGE), which has soared 13,604.64% since the year began. However, even DOGE’s weekly gains of 102.68% are weaker than those of ETC. DOGE traded 6.63% higher at $0.63 at press time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":11,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}